NasdaqGM:CRSPBiotechs
Assessing CRISPR Therapeutics (CRSP) Valuation After Upsized US$550m Convertible Notes Offering
CRISPR Therapeutics (CRSP) has completed a private offering of US$550 million in convertible senior notes due 2031, upsized from an initially announced US$350 million, drawing investor attention to its funding mix.
See our latest analysis for CRISPR Therapeutics.
The financing news has arrived during a weak patch for the shares, with a 1-day share price return showing a 5.44% decline and a 7-day share price return showing a 16.78% decline. This comes even as the 1-year total shareholder...